

Resource Summary Report

Generated by RRID on Sep 8, 2026

MDA-MB-231-Luc [JCRB]

RRID:CVCL_JG53

Type: Cell Line

Proper Citation

RRID:CVCL_JG53

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_JG53

Proper Citation: RRID:CVCL_JG53

Description: Cell line MDA-MB-231-Luc [JCRB] is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Comments: Population: Caucasian., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-231-Luc [JCRB]

Cross References: cancercellines:CVCL_JG53, JCRB:JCRB1559, Wikidata:Q54904597

ID: CVCL_JG53

Hierarchy: cvcl_0062

Record Creation Time: 20220427T220755+0000

Record Last Update: 20260905T181122+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-231-Luc [JCRB].

No alerts have been found for MDA-MB-231-Luc [JCRB].

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 180 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Ogawa A, et al. (2025) Adenosine kinase and ADAL coordinate detoxification of modified adenosines to safeguard metabolism. *Cell*.

Abuhelal S, et al. (2023) Development of Cationic Lipid LAH4-L1 siRNA Complexes for Focused Ultrasound Enhanced Tumor Uptake. *Molecular pharmaceutics*, 20(5), 2341.

Li H, et al. (2023) CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. *Proceedings of the National Academy of Sciences of the United States of America*, 120(6), e2212072120.

Chen YM, et al. (2023) Anomanolide C suppresses tumor progression and metastasis by ubiquitinating GPX4-driven autophagy-dependent ferroptosis in triple negative breast cancer. *International journal of biological sciences*, 19(8), 2531.

Tong Y, et al. (2023) Programming inactive RNA-binding small molecules into bioactive degraders. *Nature*, 618(7963), 169.

Xu F, et al. (2023) C1ql4 regulates breast cancer cell stemness and epithelial-mesenchymal transition through PI3K/AKT/NF- κ B signaling pathway. *Frontiers in oncology*, 13, 1192482.

Hu H, et al. (2023) Eupalinolide J Inhibits Cancer Metastasis by Promoting STAT3 Ubiquitin-Dependent Degradation. *Molecules (Basel, Switzerland)*, 28(7).

Challa S, et al. (2022) Development and characterization of new tools for detecting poly(ADP-ribose) in vitro and in vivo. *eLife*, 11.

Li X, et al. (2022) CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1. *Journal of experimental & clinical cancer research : CR*, 41(1), 149.

Wu M, et al. (2022) Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. *Nature communications*, 13(1), 1371.

Wang J, et al. (2022) Recombinant Oncolytic Adenovirus Combined with Cyclophosphamide Induces Synergy in the Treatment of Breast Cancer in vitro and in vivo. *Cancer management and research*, 14, 2749.

Wang L, et al. (2022) Circulating galectin-3 promotes tumor-endothelium-adhesion by upregulating ICAM-1 in endothelium-derived extracellular vesicles. *Frontiers in pharmacology*, 13, 979474.

Pham DV, et al. (2022) Adiponectin triggers breast cancer cell death via fatty acid metabolic reprogramming. *Journal of experimental & clinical cancer research : CR*, 41(1), 9.

Vecchi L, et al. (2022) Interleukin-6 Signaling in Triple Negative Breast Cancer Cells Elicits the Annexin A1/Formyl Peptide Receptor 1 Axis and Affects the Tumor Microenvironment. *Cells*, 11(10).

Yao Y, et al. (2022) A pan-cancer analysis of ring finger protein 135 and its relationship to triple-negative breast cancer proliferation and metastasis. *Aging*, 14(23), 9758.

Engelmann J, et al. (2022) Regulation of bone homeostasis by MERTK and TYRO3. *Nature communications*, 13(1), 7689.

Zheng J, et al. (2022) Morphological Dependence of Breast Cancer Cell Responses to Doxorubicin on Micropatterned Surfaces. *Polymers*, 14(14).

Huang L, et al. (2022) Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer. *Molecular cancer*, 21(1), 45.

Kim M, et al. (2022) A MYC-ZNF148-ID1/3 regulatory axis modulating cancer stem cell traits in aggressive breast cancer. *Oncogenesis*, 11(1), 60.

Yi B, et al. (2022) CRISPR interference and activation of the microRNA-3662-HBP1 axis control progression of triple-negative breast cancer. *Oncogene*, 41(2), 268.